Labcorp (LH) Q2 2026 Earnings Call Transcript
Thursday, July 30, 2026 at 9:00 a.m. ET CALL PARTICIPANTS Senior Vice President, Investor Relations - Dewey Steadman Chairman and Chief Executive Officer - Adam Schechter Executive Vice President and Chief Financial Officer - Julia Wang TAKEAWAYS Enterprise Revenue -- $3.7 billion, up 5.8% year over year, driven by 4.2% organic growth and 1.2% contribution from net acquisitions.
How this was made
The 30-second read
Why it matters
Traders can update models using the raised full-year revenue and adjusted EPS ranges, plus the maintained FCF guidance, while stress-testing for payer-driven volume headwinds and next-year PAMA pricing pressure.
Market read
Raised 2026 guidance and margin expansion are the primary upside catalysts, while cash flow decline and quantified policy headwinds are key counterweights.
What to watch
ACA headwind is quantified (20 to 30 bps in the quarter, 30 bps full-year), and PAMA is flagged as a next-year pricing pressure that could cap multiple expansion despite raised guidance.
Background
The text is a transcript-style summary of Labcorp’s Q2 2026 earnings call, including segment performance, capital allocation, and updated 2026 guidance.
Ticker impact
Labcorp raised full-year 2026 enterprise revenue guidance to 5.4% to 6.3% and adjusted EPS to $18.10 to $18.55 on the call.
Likely upward bias for LH into the next session as traders digest raised revenue and EPS ranges, tempered by FCF softness.
The article discloses specific, time-sensitive guidance updates (revenue, adjusted EPS, segment revenue, and FCF) and quantifies key offsets (ACA headwind, PAMA risk, FCF down year over year).
Market effects
Signals continued demand strength in specialty testing and Central Laboratories, potentially supporting sentiment across clinical diagnostics and lab services peers.
Limited explicit regional detail, but ACA/Medicaid utilization headwinds highlight US payer policy sensitivity for lab volumes.
Mentions foreign currency tailwinds in BLS growth, implying FX remains a swing factor for reported growth.
Counterpoint
FCF fell to $314 million from $543 million year over year, so the equity reaction could fade if investors prioritize cash conversion over earnings growth.
Key entities
- companyLabcorp Holdings Inc.
US clinical diagnostics and biopharma laboratory services provider reporting Q2 2026 results and raising full-year guidance.
- executiveAdam Schechter
CEO who discussed specialty testing growth and early signals for the ColoSense launch.
- executiveJulia Wang
CFO who quantified ACA volume headwinds and discussed backlog conversion and volume metrics.
